142 related articles for article (PubMed ID: 35864744)
1. Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Ito K; Kita Y; Yokomizo A; Miki J; Yoshio Y; Matsumoto H; Segawa T; Karashima T; Nishiyama N; Imai K; Suekane S; Nagasawa S; Higashi S; Nishiyama H; Kitamura H; Kobayashi T
Cancer Med; 2023 Feb; 12(3):2325-2332. PubMed ID: 35864744
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction.
Kita Y; Ito K; Kanda S; Joraku A; Yamaguchi R; Shimizu Y; Hayata N; Somiya S; Shibasaki N; Kimura T; Hikami K; Yamada T; Abe T; Tsuchihashi K; Tatarano S; Nishiyama H; Kitamura H; Kobayashi T
Urol Oncol; 2022 Sep; 40(9):410.e11-410.e18. PubMed ID: 35551861
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2021 Dec; 39(12):834.e21-834.e28. PubMed ID: 34284929
[TBL] [Abstract][Full Text] [Related]
8. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
Taguchi S; Kawai T; Nakagawa T; Miyakawa J; Kishitani K; Sugimoto K; Nakamura Y; Kamei J; Obinata D; Yamaguchi K; Kaneko T; Yoshida K; Yamamoto S; Kakutani S; Kanazawa K; Sugihara Y; Tokunaga M; Matsumoto A; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Ishikawa A; Tanaka Y; Nagase Y; Fujimura T; Fukuhara H; Takahashi S; Kume H
Int J Urol; 2022 Dec; 29(12):1462-1469. PubMed ID: 35996761
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
Sano T; Aizawa R; Ito K; Nakamura K; Ogata T; Takeda M; Hamada A; Matsuoka T; Kono J; Kita Y; Masui K; Goto T; Sawada A; Akamatsu S; Ogawa O; Mizowaki T; Kobayashi T
Anticancer Res; 2023 May; 43(5):2119-2126. PubMed ID: 37097696
[TBL] [Abstract][Full Text] [Related]
10. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Shindo T; Maehana T; Tanaka T; Hashimoto K; Kobayashi K; Takahashi A; Hotta H; Kunishima Y; Taguchi K; Tachiki H; Ito N; Matsukawa M; Kato R; Miyamoto S; Hinotsu S; Masumori N
Int J Urol; 2022 Sep; 29(9):1010-1016. PubMed ID: 35654444
[TBL] [Abstract][Full Text] [Related]
11. Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
Plais H; Dumont C; Gauthier H; Culine S
Immunotherapy; 2023 Jul; 15(10):729-735. PubMed ID: 37139988
[TBL] [Abstract][Full Text] [Related]
12. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M; Fava P; Stanganelli I; Ribero S; Pigozzo J; Di Giacomo AM; Ridolfi L; Tronconi MC; Trojaniello C; Bersanelli M; Garutti M; Indini A; De Risi I; De Tursi M; Merelli B; Morgese F; Occelli M; Cappellini GCA; Poletto S; Fedele D; Brugnara S; Frisinghelli M; Formisano L; Conca R; Tucci M; Russillo M; Ceroni L; Queirolo P; Targato G; Strippoli S; Mandalà M; Guida M; Quaglino P
Eur J Cancer; 2023 Jul; 187():25-35. PubMed ID: 37099946
[TBL] [Abstract][Full Text] [Related]
16. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
[TBL] [Abstract][Full Text] [Related]
17. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Harada M; Negishi T; Sakamoto N; Song Y; Hori Y; Tomoda T; Tamura S; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Clin Genitourin Cancer; 2022 Oct; 20(5):499.e1-499.e8. PubMed ID: 35624001
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
